JPRN-UMIN000013975
Completed
未知
Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurity - IVR for ROP
agoya University hospital ophtalmoligy0 sites30 target enrollmentMay 19, 2014
Conditionsretinopathy of prematurity
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- retinopathy of prematurity
- Sponsor
- agoya University hospital ophtalmoligy
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •inflammation around the eye
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Vitreous injection of anti vascular endothelium growth factor for macular edema.JPRN-UMIN000012094Mie University Schoolof Medicine100
Not yet recruiting
Not Applicable
Intravitreal aflibercept injection for exudative age-related macular degeneratioAge-Related Macular DegenerationJPRN-UMIN000010997Department of Ophthalmology, Fukushima Medical University School of Medicine50
Active, not recruiting
Phase 1
eovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroidal melanomaEUCTR2016-003329-40-FRCHU de Nice56
Completed
Not Applicable
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularizatioSubfoveal type 2 choroidal neovascularizationJPRN-UMIN000016870agoya City University Graduate School of Medicine20
Not yet recruiting
Not Applicable
A clinical study to determine the safety and performance of Everads Injector for Injection of triamcinolone acetonide in suprachoroidal space of eye.Health Condition 1: E103- Type 1 diabetes mellitus with ophthalmic complicationsHealth Condition 2: E113- Type 2 diabetes mellitus with ophthalmic complicationsCTRI/2024/01/061410Everads Therapy Ltd.